Viome Life Sciences

Viome Life Sciences is a Bellevue, Washington-based health technology company founded in 2016 by Naveen Jain, Momo Vuyisich, and Guruduth Banavar. Its mission is to make illness optional by leveraging molecular-level biological insights to predict and prevent chronic diseases, cancers, and aging. The company's core technology is a metatranscriptomic profiling platform originally developed at Los Alamos National Laboratory and exclusively licensed to Viome, enabling it to analyze both microbial and human gene expression (mRNA) — a capability it describes as unique among direct-to-consumer health tests.

Viome's flagship product is its Gut Intelligence Test, a stool-based RNA sequencing test that identifies and quantifies living microorganisms down to 1 part per million. The company has expanded into oral microbiome testing and launched its Gut Intelligence Test in 200 CVS stores across the US. It has accumulated metadata from over 300,000 specimens and is collaborating with Scripps Research on early biomarker detection for colorectal cancer using AI-trained predictive models.

Viome has raised substantial funding, including an $86.5 million Series C and a subsequent $25 million Series D round backed by investors such as Khosla Ventures and Marc Benioff, to expand its diagnostic division and personalized health offerings. Frost & Sullivan named Viome its 2019 Company of the Year in direct-to-consumer microbiome testing. An innovation in AI-driven microbiome diagnostics or metatranscriptomic analysis is directly relevant to Viome's core scientific and commercial strategy.